|
KMID : 1137020140250010043
|
|
Journal of Gynecologic Oncology
2014 Volume.25 No. 1 p.43 ~ p.50
|
|
|
Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
|
|
Kajiyama Hiroaki
Sekiya Ryuichiro
Shibata Kiyosumi
Mizuno Mika
Umezu Tomokazu
Suzuki Shiro
Niimi Kaoru
Mitsui Hiroko
Yamamoto Eiko
Kawai Michiyasu
Nagasaka Tetsuro
Kikkawa Fumitaka
|
|
|
Abstract
|
|
|
Objective: This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and postrecurrence survival (PRS) of patients with recurrent ovarian cancer, when stratifying the histologic type.
Methods: Five hundred and seventy-four patients with recurrent ovarian cancer with sufficient clinical information, including front-line chemotherapy, were analyzed. The pathologic slides were evaluated by central pathologic review. The patients were divided into two groups: group A (n=261), who underwent taxane plus platinum, and group B (n=313), who underwent conventional platinum-based chemotherapy without taxanes.
Results: The median age was 54 years (range, 14 to 89 years). Group A had significantly better median OS (45.0 months vs. 30.3 months, p<0.001) and PRS (23.0 months vs. 13.0 months, p<0.001) compared to group B. The OS and PRS were similar between the groups in patients with clear cell or mucinous histology. In contrast, among patients with non-clear cell, non-mucinous histologies, the OS and PRS of group A were significantly better than those of group B (OS, p<0.001; PRS, p<0.001). Multivariable analyses revealed that, among patients with non-clear cell, non-mucinous histologies, chemotherapy including taxane and platinum was an independent predictor of favorable survival outcomes. Conversely, in patients with clear cell or mucinous histology, taxane-including platinum-based combination chemotherapy did not improve the OS and PRS compared to a conventional platinum-based regimen which did not include taxanes.
Conclusion: Since the emergence of taxane plus platinum, the prognosis of patients with recurrent ovarian cancer has improved. However, we here demonstrate that this improvement is limited to patients with non-clear cell, non-mucinous histologies.
|
|
|
KEYWORD
|
|
|
Chemotherapy, Histologic type, Overall survival, Postrecurrence survival, Recurrent ovarian cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|